CJC-1295 ipamorelin dosage, reviewed from the literature: component-level trial data, reconstitution math for a pre-mixed 10 mg vial, half-life context and data limits. Research use only.
"CJC-1295 ipamorelin dosage" is one of the most searched questions in the growth-hormone-secretagogue category, and it has an awkward answer: there is no published human dosing study of the two compounds administered together. Every figure attached to the blend is assembled from component-level data — a GHRH-analogue literature on one side, a ghrelin-receptor-agonist literature on the other, and a well-replicated receptor-class synergy connecting them. This page lays out what each literature actually administered, how a pre-mixed vial changes the arithmetic, and where the data stops. It is a literature review, not a protocol.
Dosing literature is generated by trials, and no peer-reviewed randomized trial of CJC-1295 plus ipamorelin has been published. The combination rests on a receptor-level finding: Bowers and colleagues (JCEM, 1990) gave healthy men a synthetic GH-releasing peptide and GHRH and found that submaximal doses of the two together released GH synergistically — more than the sum of each alone. That study used a different GHRP and native GHRH, intravenously, in micrograms per kilogram. It establishes the mechanism; it does not supply a dose for this blend.
The practical consequence is that any "blend dose" is really two component doses sharing a syringe. Reading it correctly means reading each component's data separately — the full mechanistic background is in the CJC-1295 + ipamorelin research overview.
CJC-1295 is sold in two forms whose pharmacokinetics differ by orders of magnitude.
Blends are conventionally formulated with the no-DAC form, because a multi-day GHRH plateau does not pair meaningfully with a two-hour GHRP pulse. That convention should be verified against the label and Certificate of Analysis rather than assumed. Detailed figures for each form are in CJC-1295 dosage — research dosing notes.
Human pharmacokinetic work (Gobburu et al., Pharmaceutical Research, 1999) administered ipamorelin intravenously across roughly 1 to 100 µg/kg in healthy men and reported dose-proportional kinetics, a terminal half-life of about two hours, and a single GH episode peaking at roughly 40 minutes. The only efficacy trial — a phase 2 postoperative-ileus study (NCT00672074) — used 0.03 mg/kg intravenously twice daily and was discontinued after missing its primary endpoint.
Two caveats carry over directly to the blend. The human route was intravenous, not subcutaneous, so exposure does not translate one-to-one. And a dose appearing in a failed trial describes what was studied, not what worked. The full ipamorelin figures are in ipamorelin dosage — research dosing notes.
The CJC-1295 + Ipamorelin blend ships as a 10 mg lyophilized vial — 10 mg is the combined peptide mass, not the mass of each component. The per-component split determines every downstream number, so it should be read from the label or CoA first. Using a 5 mg + 5 mg split as a worked example:
| Diluent | Total concentration | Per component | One U-100 unit (0.01 mL) | Ten units (0.10 mL) |
|---|---|---|---|---|
| 2 mL | 5 mg/mL | 2.5 mg/mL each | 50 µg total (25 µg each) | 500 µg total (250 µg each) |
| 3 mL | 3.33 mg/mL | 1.67 mg/mL each | 33 µg total (~17 µg each) | 333 µg total (~167 µg each) |
| 4 mL | 2.5 mg/mL | 1.25 mg/mL each | 25 µg total (12.5 µg each) | 250 µg total (125 µg each) |
The table exposes the blend's defining constraint: the ratio is fixed at manufacture. Every draw delivers both compounds in the same proportion, so neither can be adjusted independently. Research designs that need to vary one variable — for example, holding the GHRH analogue constant while titrating the GHRP — require separate vials of CJC-1295 no DAC and ipamorelin. Changing diluent volume changes concentration, not ratio.
The method behind the table — concentration equals peptide mass divided by diluent volume — is covered step by step in the dosing math guide, with solvent selection, mixing and post-reconstitution storage in reconstitution 101.
With no combination trial, cadence can only be reasoned from half-life. Both components in a no-DAC blend are short-acting, so each administration models a single discrete GH pulse rather than a sustained elevation. That is why the conventions circulating for blends describe once- or twice-daily administration rather than weekly schedules — a convention derived from pharmacokinetics and practice, not from a dose-finding study.
Timing relative to meals is also discussed in secretagogue research because GH responses are known to be blunted by elevated glucose and free fatty acids. That is general endocrine physiology, not a finding specific to this blend, and it has not been quantified for these compounds.
The evidence base for "CJC-1295 ipamorelin dosage" is: one well-designed human PK study of the DAC form (not the form typically blended), one human PK study of intravenous ipamorelin, one discontinued ipamorelin phase 2, a halted CJC-1295 phase 2, and a 1990s receptor-class synergy literature using different molecules. There is no long-term human safety record for either compound, alone or together. Both are prohibited in sport under section S2 of the WADA Prohibited List. Any precise blend dose presented as established is extrapolation.
Is there a published dose for CJC-1295 and ipamorelin together? No. No peer-reviewed human trial of the combination has been published. Figures attached to the blend are derived from separate component studies and from receptor-class synergy work such as Bowers et al. (1990), which used different molecules intravenously.
Is the 10 mg on the blend vial per compound or combined? Combined. The 10 mg figure is total peptide mass; the per-component split should be confirmed on the label or Certificate of Analysis before any concentration math is done.
Why do blend conventions differ so much from CJC-1295 trial doses? Because the published CJC-1295 trials used the DAC form, weight-scaled in µg/kg on a weekly cadence. Blends conventionally contain the short-acting no-DAC form, which has no equivalent published human dosing study.
Can the ratio in a pre-mixed vial be changed? No. Diluent volume changes concentration, not the ratio between components. Varying one compound independently requires separate vials.
Is any of this a dosing recommendation? No. These are research-grade materials for laboratory use only, not for human or veterinary consumption. Every figure here describes published study parameters or reconstitution arithmetic, not medical advice.
